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Abstract:  
 
Background: Total CD4+ T-cell counts predict HIV disease progression, but do 
not necessarily reflect normalization of immune function. CD4/CD8 ratio is a 
marker of immune dysfunction, a prognostic indicator for non-AIDS mortality, 
and reflects viral reservoir size.  Despite ART, recovery of CD4/CD8 ratio in 
chronic HIV infection is incomplete; we hypothesize enhanced CD4/CD8 ratio 
recovery with earlier treatment initiation in recently infected individuals. 
Methods:  CD4+ count and CD4/CD8 ratio were analyzed using data from two 
cohorts: SPARTAC trial, and the UK HIV Seroconverters Cohort where Primary 
HIV infection (PHI) was defined as within 6 months from estimated date of 
infection.  Using time-to-event methods and Cox proportional hazard models we 
examined the effect of CD4/CD8 ratio at seroconversion on disease progression 
(CD4<350 cells/mm3/ART initiation), and factors associated with time from ART 
initiation to CD4/CD8 normalization (ratio >1.0). 
Findings:  Of 573 seroconverters, 482 (84%) had abnormal CD4/CD8 ratios at 
HIV seroconversion. Individuals with higher CD4/CD8 ratio at seroconversion 
were significantly less likely to reach the disease progression end point (aHR 
[95% CI] = 0.52 [0.32, 0.82], p=0.005).  The longer the interval between 
seroconversion and ART initiation (HR [95% CI] =0.98 per month increase 
[0.97, 0.99], p<0.001) the less likely CD4/CD8 ratio normalization.  ART 
initiation within 6 months from seroconversion was significantly more likely to 
normalize (HR [95% CI] =2.47 [1.67, 3.67], p<0.001) than those initiating 
later.  
Interpretation: The majority of individuals presenting in PHI have abnormal 
CD4/CD8 ratios. The sooner ART is initiated in PHI the greater the probability of 
achieving normal CD4/CD8 ratio. 
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Background 
Total CD4+ T-cell count is a validated surrogate marker of disease progression 
for HIV/AIDS (1-3).  Whilst the risk of AIDS related illness and opportunistic 
disease is significantly reduced once CD4 counts have recovered to levels >350 
cells/mm3 (4-6), the risk of non-AIDS morbidity persists (7).  Despite recovery 
of total CD4+ T-cell counts with ART, the CD4/CD8 ratio often fails to normalise 
(defined as > 1) when ART is initiated in chronic infection (8) where reported 
normalization of CD4/CD8 ratio ranges from 6-26.3% (3, 9-11). A recent study 
from a large Italian cohort reported a normalisation rate of 29.4% despite 5 
years of viral suppression on ART (12). 
 
Disruption of T-cell homeostasis by HIV induces CD4+ depletion and CD8+ T-cell 
expansion resulting in an inverted CD4/CD8 ratio (13, 14).  Low CD4/CD8 ratio 
in individuals on suppressive ART has been independently associated with 
persistently elevated markers of T-cell activation (8), and measures of HIV viral 
reservoirs (15, 16). In untreated HIV infection CD4/CD8 ratio inversely 
correlates with marker of T cell activation and exhaustion (17).  In addition low 
CD4/CD8 ratio independently predicts all-cause mortality and non-AIDS related 
events (17). CD4/CD8 T-cell ratio may therefore better predict immune function 
than total CD4+ count alone (17, 18) and may contribute to the observed START 
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trial result, identifying a significantly enhanced clinical outcome for individuals 
starting ART at CD4 counts > 500 cells/mm3  (19),   
 
Enhanced normalisation of the CD4 T-cell count with ART initiated within four 
months of seroconversion has recently been demonstrated (20).  We 
hypothesised that CD4/CD8 ratio recovery would also be enhanced following 
immediate ART initiation initiated in PHI. We examined the dynamics of immune 
recovery by combining data from two cohorts of individuals with well-estimated 
dates of HIV seroconversion.  
 
 
Methods  
 
Cohort descriptions 
 
The two cohorts have been described previously (21, 22). Briefly, the UK HIV 
Seroconverters Cohort (UKHSC) is an observational cohort of routine clinic data 
from individuals with defined HIV seroconversion dates collected between 1994-
2014. Data were restricted to 2 clinical centers able to provide CD8 T cell data 
as these were not routinely collected within UKHSC. SPARTAC (Short Pulse Anti-
Retroviral Therapy at Seroconversion) is an international randomized clinical trial 
of two intervention arms in PHI; 12 weeks or 48 weeks of transient therapy vs. 
deferred treatment (standard of care) across 8 countries.  
 
Study definitions 
 
A normal CD4/CD8 T-cell ratio was defined as ≥ 1.0 (23). Primary HIV infection 
(PHI) was defined as documented HIV infection within a maximum of 6 months 
from a previous negative HIV antibody test, p24 antigen positive in the absence 
of antibody or an ‘incident’ RITA Recent incidence test algorithm test (21). 
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Disease progression was defined as CD4<350 cells/mm3 or long-term ART 
initiation. 
 
Statistical analysis 
 
We examined the effect of CD4/CD8 ratio at PHI (baseline) on time to disease 
progression endpoint using time-to-event methods and Cox proportional hazards 
models, restricting to individuals with CD4+>350 cells/mm3 at time of PHI 
diagnosis.  Baseline CD4/CD8 ratio was included as a continuous variable then 
as a categorical variable (<0.5, 0.5 – 1.0, 1.0).  The multivariate analyses were 
adjusted for sex, age at PHI, risk group, ethnicity and enrolment from an African 
site (as proxy for ethnicity), baseline CD4 count and HIV-1 viral load.   Follow-up 
was censored at date last recorded result. We checked for collinearity between 
baseline CD4 and baseline CD4/CD8 ratio. 
 
We then examined the effect of the interval between PHI and ART initiation on 
time from ART initiation to normalized CD4/CD8 ratio, again using time-to-event 
methods and Cox proportional hazards models.  All models were censored at the 
earlier of a break in ART treatment (>7 days) or last visit before 24th April 2014, 
whichever was earlier.   Multivariate analyses were adjusted for sex, risk group, 
ethnicity, ART regimen, enrolment from an African site, year of seroconversion, 
interval between baseline ratio and ART initiation, and both CD4+ count, HIV-1 
viral load and age at ART initiation. For illustration purposes we used an 
arbitrary cut-off of 6 months to examine the effect of a dichotomised duration of 
HIV infection at initiation of ART; ART started <6 months and ART initiated ≥6 
months of estimated date of seroconversion. The cut-off for a normal CD4/CD8 
ratio of 1.2 has been used by some groups (3, 9); a sensitivity analysis was 
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performed using this value.  A further sensitivity analysis was performed using a 
cut-off of 0.5. 
 
Findings 
Overall, 573 individuals contributed CD4/CD8 data of whom 482 (84%) had 
abnormal CD4/CD8 ratios (<1.0) at baseline in PHI.  Information was not 
available on Fiebig staging though the vast majority were at stage V or VI.  Of 
84, 155 and 334 individuals presenting with CD4+ counts <350, 350-500, and 
>500 cells/mm3, 95% (n=80), 91% (n=141) and 78% (n=261) had abnormal 
CD4/CD8 ratios, respectively. The median CD4/CD8 ratio (IQR) at baseline in 
PHI was 0.30 (0.21, 0.42) for those with CD4 count <350 cells/mm3, 0.46 (0.31, 
0.66) for those with CD4 350-500 cells/mm3 and 0.55 (0.35, 0.80) if CD4 was 
>500 cell/mm3. 
Of 286 ART-naïve individuals with baseline CD4 counts > 350 cells/mm3, the 
median time to the disease progression end point was 1.51 [95%CI 1.32, 2.37] 
years. Higher CD4/CD8 ratio at seroconversion was independently associated 
with lower risk of endpoint (aHR [95% CI] =0.52 [0.32, 0.82], p=0.005), as was 
higher baseline CD4 count (aHR [95% CI] 0.79 per 100 cell increase [0.71,0.86] 
p<0.001)”  
Compared to individuals with CD4/CD8 ratio >1.0 at PHI, those with lower ratios 
had greater risk of disease progression; (CD4/CD8 ratio <0.5: HR [95%CI] = 
2.89 [1.74, 4.79], p<0.001, CD4/CD8 ratio >0.5-≤1.0: HR [95%CI] = 1.97 
[1.17, 3.30], p=0.010) see Figure 1b).   
We found strong evidence that those with longer time between PHI and ART 
initiation were less likely to achieve normal CD4/CD8 ratio (aHR [95%CI]=0.98 
per month increase [0.97, 0.99], p<0.001) after adjusting for confounding 
variables (including baseline HIV-1 Viral load and CD4 count). The only other 
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significant covariate in the model was baseline CD4+ cell count with 
normalization more likely as count increased (HR=1.12 [95%CI 1.09, 1.15] per 
50 cell/mm3 increase, p<0.001).  Results from the sensitivity analysis (normal 
CD4/CD8 ratio >1.2 and >0.5) were qualitatively unchanged.   
  
Of 468 individuals with abnormal CD4/CD8 ratio initiating ART, 309 commenced 
ART within 6 months, and 159 initiated ≥6 months from seroconversion.  Their 
baseline characteristics are shown in table 1.  Overall median [95%CI] time to 
normalization of CD4/CD8 ratio was 715 [408, 988] days; 172 [117, 280] days 
for those in the <6 months group, and 1344 [1080, 1630] days in the ≥6 
months group.  Those initiating ART within 6 months from seroconversion were 
significantly more likely to normalise the CD4/CD8 ratio (HR [95%CI] =2.47 
[1.67, 3.66], p<0.001), see figure 1a.  In addition, within one year from the 
date of starting ART; 129/275 (46.9%) individuals in the <6 month group 
normalized the CD4/CD8 ratio, compared with 16/127 (12.6%) in the ≥6 month 
group. A figure illustrating the dynamics of the CD4 and CD8 T cells counts for 
each group is shown in (see Figure S2, Supplemental Digital Content, 
http://links.lww.com/QAI/A810). 
 
Interpretation 
  
Our findings demonstrate that ART initiated within 6 months from PHI markedly 
increases the likelihood of normalization of the CD4/CD8 ratio compared with 
later initiation of therapy, irrespective of baseline CD4 count. This is in 
agreement with Serrano-Villar et al (24). In addition we found that the 
probability of achieving normalization of CD4/CD8 ratio is increased for each 
month closer to seroconversion ART is initiated. The normalization of CD4/CD8 
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ratio is relatively rapid with almost half of the individuals achieving this within 1 
year of ART initiation. This finding is in contrast to the reported normalization 
rates of CD4/CD8 ratio in treated chronic HIV infection (3, 10, 11); where the 
chances of normalization within 1 year of ART initiation remain low, and are 
comparable to those initiating ART ≥ 6 months in our study.  Higher rates of 
CD4/CD8 ratio normalization have been reported in two studies of treated 
chronic infection, but only following up to a median of 10 years on ART, (9, 25).  
Previously, International treatment guidelines have varied on the CD4 count 
threshold that ART initiation is recommended (26-28), with inconsistent 
guidelines on starting ART in PHI. However, in light of the recent findings 
reported by the START study (19), ART initiation regardless of CD4 T count will 
be recommended by all international guidelines (29), which will include 
immediate ART initiation in PHI. In this setting, PHI represents a specific 
scenario; despite abnormal CD4/CD8 ratios in the majority of individuals at the 
time of seroconversion, irrespective of initial CD4 count, rapid ART initiation 
confers a significantly enhanced probability of immunological recovery, which 
has not been observed in later stage disease. Furthermore, given the high rate 
of serious non-AIDS events at relatively high CD4 counts seen in START, 
exploration of other biomarkers predictive of disease progression such as 
CD4/CD8 ratio is warranted.  
There are limitations to our study. As with all observational studies, it is not 
possible to adjust for unmeasured confounders. For example, abnormal 
CD4/CD8 ratio has been associated with CMV infection seropositivity (30).  As 
CMV data were not available from our cohorts, we were unable to adjust for CMV 
infection. Further, abnormal CD4/CD8 is known to increase with age (31). Given 
the relatively young, median age of 34 years, of our cohort, we could not 
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address the role of CD4/CD8 recovery in age groups >50 years, who are known 
to progress faster (32). In addition, the majority of those treated within 6 
months received a boosted PI-based regimen, reflecting the SPARTAC trial 
protocol of short-course ART, to avoid the risk of resistance to non-nucleoside 
reverse-transcriptase inhibitors (NNRTIs) on stopping owing to their differential 
clearance (33, 34).  Those initiated beyond 6 months primarily received NNRTI- 
based regimens in keeping with local guidelines. We, therefore, included ART 
class in the model and found no evidence of an effect on CD4/CD8 ratio 
normalisation. 
CD4/CD8 ratio may have additional potential uses as a biomarker in HIV cure 
research.  Whilst there remains a lack of consensus as to the optimal 
measurement of viral reservoir (35), quantification of reservoir size using total 
cellular HIV-1 DNA remains the best clinical biomarker to predict both disease 
progression and virological rebound amongst individuals interrupting ART (15, 
36).  Although HIV-1 DNA was not measured for all individuals in this study, an 
analysis of a subset of individuals from the SPARTAC trial found an inverse 
correlation between HIV-1 DNA and CD4/CD8 ratio (37). As such, normalization 
of CD4/CD8 ratio maybe a future valuable biomarker which better predicts those 
individuals with a smaller HIV reservoir. This could inform an algorithm to 
identify optimal candidates for cure interventions or treatment interruption. 
Furthermore if CD4/CD8 ratio reflects HIV reservoir size, then our data support 
the finding by other groups that treatment with ART at PHI may limit HIV 
reservoir size (38). 
In conclusion, CD4/CD8 ratio normalization, albeit rare when ART is started in 
chronic infection, is markedly enhanced with ART initiation in PHI, with a greater 
benefit the sooner ART is started. 
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Figure 1a. Kaplan-Meier plots of the probability of time to normalization of the 
CD4/CD8 ratio for those initiated on antiretroviral therapy (ART) within six months of 
estimated date of seroconversion and those who deferred ART to more than or equal to 
six months. 
 
Figure 1b. Kaplan-Meier plots of the probability of initiating ART or CD4 count <350 
according to CD4/CD8 ratio group at seroconversion: (a) Ratio <0.5, (b) ≥0.5 and (c) 
≤1.0, or >1.0. This analysis used data (n=286) those from the UK Register of 
Seroconverters and SPARTAC (including only those who were not randomized to 
starting treatment) 
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Table 1:  Baseline characteristics of HIV seroconverters 
presenting during PHI by time from seroconversion to ART 
initiation 
 
 
 
 
Initiated ART <6 
months 
after HIV SC 
N=309  
Initiated ART 
≥6 months 
after HIV SC 
N=159 
Total 
N=468 
    
Male 219 (70.9%) 144 (90.6%) 363 (77.6%) 
Ethnicity     
      White 123 (39.8%) 101 (63.5%) 224 (47.9%) 
      Black 13 (4.0 %) 7 (4.4%) 20 (4.3%) 
    Other/Unknown 173 (56.0%) 51 (32.1%) 224 (47.9%) 
Risk group    
    MSM 203 (65.9%) 138 (86.8%) 341 (73.0%) 
    MSW 103 (33.4%) 19 (12.0%) 122 (26.1%) 
    IDU 1 (0.3%) 0 (0.0%) 1 (0.2%) 
    Unknown 1 (0.3%) 2 (1.3%) 3 (0.6%) 
Initial drug regimen    
    PI based regimen 251 (81.2%) 33 (20.8%) 284 (60.7%) 
    NNRTI based regimen 49 (15.9%) 111 (69.8%) 160 (34.2%) 
    NNRTIs only 1 (0.3%) 11 (6.9%) 12 (2.6%) 
    Other 8 (2.6%) 4 (2.5%) 12 (2.6%) 
Time in month from SC to ART 
Initiation: median (IQR) 
2.48 
(1.33, 3.35) 
29.07 
(15.2, 51.1) 
3.37 
(1.93, 16.07) 
Age (years) at ART initiation: 
median (IQR) 
33 
(27, 41) 
38 
(30, 42) 
34 
(27, 41) 
CD4 count/mm3 at ART 
initiation: median (IQR) 
547 
(408, 687.0) 
290 
(220, 400) 
465 
(307, 622) 
CD8 count/mm3 at ART 
initiation: median (IQR) 
980  
(711, 1370)  
930  
(700, 1309)  
965.5  
(710, 1350)  
CD4:CD8 ratio at ART initiation: 
median (IQR) 
0.55 
(0.36, 0.82) 
0.32 
(0.19, 0.45) 
0.45 
(0.27, 0.71) 
MSM: Men who have sex with men 
MSW: Men who have sex with women 
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Figure1: Kaplan Meier 
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